📱

Read on Your E-Reader

Thousands of readers get articles like this delivered straight to their Kindle or Boox. New articles arrive automatically.

Learn More

This is a preview. The full article is published at seekingalpha.com.

OptimizeRx Stock: A Buy-The-Dip Opportunity For This Above-Average Growth Story

OptimizeRx Stock: A Buy-The-Dip Opportunity For This Above-Average Growth Story

By David ZanoniAll Articles on Seeking Alpha

This article was written by David focuses on growth & momentum stocks that are reasonably priced and likely to outperform the market over the long-term. He is a long term investor of quality stocks and uses options for strategy. David told investors to buy in March 2009 at the bottom of the financial crisis. The S&P 500 increased 367% and the Nasdaq increased 685% from 2009 through 2019. He wants to help make people money by investing in high-quality growth stocks. Analyst’s Disclosure: I/we have a beneficial long position in the shares of OPRX either through stock ownership, options, or other derivatives. I wrote this article myself, and it expresses my own opinions. I am not receiving compensation for it (other than from Seeking Alpha). I have no business relationship with any company whose stock is mentioned in this article. The article is for informational purposes only (not a solicitation or recommendation to buy or sell stocks). David is not a registered investment adviser. Investors should do their own research or consult a financial adviser to determine what investments are appropriate for their individual situation. This article expresses my opinions and I cannot guarantee that the information/results will be accurate. Investing in stocks involves risk and could result in losses. Seeking Alpha's Disclosure: Past performance is no guarantee of future results. No recommendation or advice is being given as to whether any investment is suitable for a particular investor. Any views or opinions expressed above may not reflect those of Seeking Alpha as a whole. Seeking Alpha is not a licensed securities dealer, broker or US investment adviser or investment bank. Our analysts are third party authors that include both professional investors and individual investors who may not be licensed or certified by any institute or regulatory body.

Preview: ~298 words

Continue reading at Seekingalpha

Read Full Article

More from All Articles on Seeking Alpha

Subscribe to get new articles from this feed on your e-reader.

View feed

This preview is provided for discovery purposes. Read the full article at seekingalpha.com. LibSpace is not affiliated with Seekingalpha.

OptimizeRx Stock: A Buy-The-Dip Opportunity For This Above-Average Growth Story | Read on Kindle | LibSpace